Genetic Considerations in Hypertrophic Cardiomyopathy

Hollman, 1960, A family with obstructive cardiomyopathy (asymmetrical hypertrophy), Br Heart J, 22, 449, 10.1136/hrt.22.4.449 Konno, 2010, Genetics of hypertrophic cardiomyopathy, Curr Opin Cardiol, 10.1097/HCO.0b013e3283375698 Olivotto, 2008, Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 83, 630, 10.1016/S0025-6196(11)60890-2 Girolami F, Ho CY, Semsarian C, et al: Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 55:1444-53. Maron, 2003, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0 Gersh, 2011, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation Arad, 2005, Glycogen storage diseases presenting as hypertrophic cardiomyopathy, N Engl J Med, 352, 362, 10.1056/NEJMoa033349 Pelliccia, 2008, Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities, J Am Coll Cardiol, 52, 1990, 10.1016/j.jacc.2008.08.055 Fatkin, 2000, An abnormal Ca(2+) response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy, J Clin Invest, 106, 1351, 10.1172/JCI11093 Semsarian, 2002, The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model, J Clin Invest, 109, 1013, 10.1172/JCI200214677 Teekakirikul, 2010, Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-beta, J Clin Invest, 120, 3520, 10.1172/JCI42028 Ho, 2002, Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy, Circulation, 105, 2992, 10.1161/01.CIR.0000019070.70491.6D Crilley, 2003, Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy, J Am Coll Cardiol, 41, 1776, 10.1016/S0735-1097(02)03009-7 Ho, 2010, Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy, N Engl J Med, 363, 552, 10.1056/NEJMoa1002659 Lakdawala, 2011, Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy, J Am cardiol, 108, 1606, 10.1016/j.amjcard.2011.07.019